Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A highlight significant positive developments, including a substantial BARDA award, strong financial backing, and progress in manufacturing scale-up. Although management withheld some efficacy data, the overall sentiment is optimistic with potential market expansion and strong interest in CD388. The strategic plan and funding provide a solid foundation for future growth, outweighing concerns over interim analysis data. Given these factors, a positive stock price reaction is anticipated.
Key Financial Performance
Milestone Payment to J&J $45 million milestone payment triggered by the initiation of the Phase III ANCHOR trial in Q3 2025. This payment will be made in Q4 2025.
Cash Position Approximately $476 million in cash as of September 30, 2025. This strong financial position ensures full funding for the Phase III development program, including potential expansion to the Southern Hemisphere.
BARDA Award Award valued up to $339 million received in October 2025 to support expanded manufacturing and clinical development of CD388. The base period of the award is valued at $58 million over the first 24 months.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CD388 Phase III Development: CD388 has advanced into Phase III development on an accelerated timeline, with the ANCHOR trial starting six months earlier than planned. The trial evaluates safety and efficacy in high-risk populations for influenza.
Expanded Patient Population: Enrollment expanded to include healthy adults over 65, doubling the eligible patient population in the U.S. from 50 million to over 100 million.
Breakthrough Therapy Designation: CD388 received breakthrough therapy designation from the FDA, offering benefits like enhanced FDA access, rolling data review, and priority review eligibility.
BARDA Funding: Awarded up to $339 million from BARDA to support manufacturing and clinical development, with $58 million allocated for the first 24 months.
Market Expansion for CD388: The expanded patient population and potential approval for broader use positions CD388 as a significant player in the influenza prevention market, targeting over 100 million people in the U.S.
Clinical Trial Progress: The ANCHOR trial is over 50% enrolled, with 6,000 participants targeted across 150 sites, and is on track to complete Northern Hemisphere enrollment by December.
Manufacturing Onshoring: BARDA funding supports onshoring manufacturing to the U.S., enhancing the commercial supply chain.
R&D Day Announcement: Cidara plans to host a virtual R&D Day on December 15 to provide updates on CD388 and share market research insights.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Feedback and Trial Expansion: The expansion of the patient population for the Phase III trial based on FDA feedback, while beneficial for enrollment, introduces complexities in trial management and increases the scope of regulatory compliance.
Financial Obligations: The initiation of the Phase III ANCHOR trial triggered a $45 million milestone payment to J&J, which adds financial pressure as it will be paid in Q4.
Trial Enrollment and Execution: The need to enroll 6,000 participants across 150 sites and potentially expand to the Southern Hemisphere if enrollment targets are not met in the Northern Hemisphere adds operational challenges and risks of delays.
Manufacturing and Supply Chain: The onshoring of manufacturing to the United States and the need to expand the initial commercial supply chain introduces risks related to production scalability, cost management, and potential delays.
Dependence on External Funding: While the BARDA award provides significant financial support, the reliance on multiyear agreements with option periods introduces uncertainty if future funding is not secured.
Market Competition: CD388 faces competition from existing vaccines and antivirals, and its success depends on demonstrating clear advantages in efficacy, safety, and cost-effectiveness.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Phase III Development of CD388: The lead candidate, CD388, has advanced into Phase III development on an accelerated timeline. The Phase III ANCHOR trial began six months earlier than planned and aims to evaluate the safety and efficacy of CD388 in high-risk populations for influenza complications. Enrollment has been expanded to include healthy adults over 65, doubling the potential eligible patient population in the U.S. from 50 million to over 100 million. The study is over 50% enrolled and is on track to achieve target enrollment in the Northern Hemisphere by December 2025. An interim analysis in late Q1 2026 will determine if additional enrollment in the Southern Hemisphere is necessary.
Regulatory and Designation Updates for CD388: CD388 received breakthrough therapy designation from the FDA in October 2025, which provides enhanced access to the FDA, rolling data review, and eligibility for priority review. This designation is expected to accelerate development and regulatory timelines. CD388 also holds fast track status.
BARDA Funding for CD388: Cidara received an award valued up to $339 million from BARDA to support expanded manufacturing and clinical development of CD388. The base period of $58 million over 24 months will fund onshoring of manufacturing to the U.S., expanded commercial supply chain, and additional clinical and nonclinical studies. Option periods could provide up to an additional $281 million for further studies in targeted and broader populations.
Financial Position and Funding: Cidara has approximately $476 million in cash as of September 30, 2025, ensuring that the Phase III development program for CD388 is fully funded through completion, including potential expansion to the Southern Hemisphere.
Future Updates and R&D Day: Cidara plans to host a virtual R&D Day on December 15, 2025, to provide updates on the CD388 program, including enrollment progress and commercial opportunities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:At the interim analysis, how will the external statistician decide how many additional patients are needed to enroll?
A:The external statistician will use a complex algorithm to determine if the powering assumptions and desired power target for the study are met. The statistician, who is independent of the study, will review the data but will not share it with the study team. They will only inform whether the current sample size of 6,000 is sufficient or if additional participants are needed.
Q:Should we expect to see any efficacy data across cohorts at the interim analysis?
A:No, the interim analysis will not provide efficacy data. The unblinded statistician will see the data but will not share it with the team. If the entire trial is enrolled in the Northern Hemisphere, there may be no need to move into the Southern Hemisphere, but this decision will not be informed by the interim analysis.
Q:Will mild patients who are immunocompromised and comorbid be included in the label if everything is positive in the Phase III trial?
A:The FDA has asked to expand trial eligibility to include individuals 65+ with low or mild comorbidities. There is potential for these patients to be included in the label, but further discussions with the FDA are required.
Q:What are the flu vaccination rates in the study, and how does it impact the trial?
A:The estimated flu vaccination rate in the study is 65%, based on prior clinical studies. However, vaccination rates in the Southern Hemisphere have been lower. The trial aims to capture real-world vaccination rates, and lower rates may favor the trial results by increasing event rates in the placebo arm.
Q:How is the manufacturing scale-up progressing, and what are the needs for scaling up?
A:Manufacturing scale-up is progressing well with WuXi, which supports clinical trials and will handle manufacturing for BLA submission and commercialization. The initial scale will produce around 5 million doses per year. Additional capacity is being developed through a U.S. supply chain and potential larger global manufacturers.
Q:What is the scale at WuXi for launch, and what is rate-limiting for the BLA filing?
A:WuXi's initial scale will produce around 5 million doses per year. The rate-limiting factor for the BLA filing is the transition from the clinical trial configuration (three injections) to a commercial configuration (single vial), along with process characterization and qualification activities.
Q:What have we learned about resistance to CD388 and why some patients were not protected?
A:Breakthrough infections may occur due to high inoculum effects, not resistance. Nonclinical data suggests CD388 is not susceptible to resistance. Virology next-generation sequencing is being conducted on observed infections, and results will be reported once analyses are complete.
Q:How does the inclusion of healthy individuals over 65 impact vaccine rates, event rates, and powering assumptions?
A:The inclusion of 65+ individuals, including healthy and mildly comorbid, has expedited enrollment and did not negatively affect sample size or powering assumptions. This population tends to have higher flu event rates and vaccination rates (~65%).
Q:What are the implications of completing enrollment by December?
A:Enrollment completion by December means participants will still be followed for six months to capture flu season event rates. This timeline aligns with the Phase IIb study, where results were available in June after the flu season.
Q:What is the potential real-world uptake of CD388 across patient segments?
A:Prescribers show strong interest in CD388 for patients with moderate to severe comorbidities and mild comorbidities. The broad market opportunity will depend on commercial reach and adoption rates, which will be detailed further at the December R&D Day.
Q:What clinical or preclinical work is planned to establish CD388's utility in a pandemic setting?
A:Studies are ongoing with St. Jude's Hospital to evaluate CD388 against pandemic strains like H5N1. Data shows robust efficacy in ferrets and activity against neuraminidase inhibitor-resistant strains. Further in vitro studies and follow-ups are planned.
Q:Review of Unclear Management Responses
A:Management avoided providing specific efficacy data at the interim analysis, citing that only the unblinded statistician would see the data. They also did not disclose real-time flu vaccination rates in the study, stating that these could change over the course of the season. Additionally, they deferred detailed discussions on real-world uptake and market penetration of CD388 to the December R&D Day.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act statement
LifeSci QA
Mr Chief
Officer today
day Cidara
filing information
information afternoon
note today
release SEC
release website
statement note
today press
uncertainty result
update press
CDTX Transcript
Cidara Therapeutics, Inc. (CDTX) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call summary and Q&A highlight significant positive developments, including a substantial BARDA award, strong financial backing, and progress in manufacturing scale-up. Although management withheld some efficacy data, the overall sentiment is optimistic with potential market expansion and strong interest in CD388. The strategic plan and funding provide a solid foundation for future growth, outweighing concerns over interim analysis data. Given these factors, a positive stock price reaction is anticipated.
Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-9
Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary and Q&A session reveal mixed signals. Financially, the company has secured significant funding, but there are concerns about funding dependency and BARDA grant uncertainty. Clinical trial execution risks and competitive pressures are notable challenges. Management's optimistic outlook on CD388's value proposition is tempered by market adoption challenges. The lack of clarity in management's responses further adds uncertainty. These factors contribute to a neutral sentiment, suggesting the stock price might not see significant movement in the short term.
Cidara Therapeutics (CDTX) Presents At Maxim Group Infectious Disease Virtual Conference - Slideshow
Neutral5-8
CDTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
